Identification and external validation of clinical-molecular features to predict benefit from oxaliplatin reintroduction/rechallenge in patients with refractory metastatic colorectal cancer (mCRC)

by on 22 de gener de 2024 with No hi ha comentaris
  • Salva, F., Paes, R., Silva, M. C. E., Cruz, H., Gonzalez, N. S., Baraibar, I., . . . Tabernero, J., Elez. E., Dienstmann, R. (2023). Identification and external validation of clinical-molecular features to predict benefit from oxaliplatin reintroduction/rechallenge in patients with refractory metastatic colorectal cancer (mCRC). Journal of Clinical Oncology, 41, 153-153. https://doi.org/10.1200/JCO.2023.41.4_suppl.153

Deixa un comentari

L'adreça electrònica no es publicarà. Els camps necessaris estan marcats amb *